Geographic atrophy (GA) is an advanced form of age-related macular degeneration characterized by the progressive degeneration of retinal cells, leading to irreversible vision loss. According to Antoine Huang et al., 2025, the global prevalence of geographic atrophy is estimated at 0.44 %, affecting approximately five million individuals worldwide. Current therapies in the GA pipeline focus on complement inhibition, gene therapy, and neuroprotective agents. According to the geographic atrophy pipeline analysis by Expert Market Research, there is a growing focus on early detection, personalized treatment approaches, and combination therapies. With increasing research investment and technological advancements, the therapeutic landscape is expected to witness significant growth in the coming years.
Major companies involved in the geographic atrophy pipeline analysis include Biojiva LLC, Janssen Research & Development, LLC, and others.
Leading drugs currently in the pipeline include BRX011, JNJ-81201887, ADX-038, and others.
The pipeline shows robust growth driven by advanced complement inhibitors, innovative gene therapies, and increased regulatory approvals, offering potential for improved treatment efficacy and broader patient access in the coming years.
The Geographic Atrophy Pipeline Analysis Report by Expert Market Research gives comprehensive insights into geographic atrophy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Geographic Atrophy. The geographic atrophy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The geographic atrophy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with geographic atrophy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to geographic atrophy.
Read more about this report - Request a Free Sample
Geographic atrophy is an advanced, progressive form of age-related macular degeneration characterized by the degeneration of retinal cells, leading to irreversible vision loss. It occurs when lesions expand across the retina, particularly affecting the fovea, which is crucial for central vision, ultimately impairing daily activities and quality of life.
Geographic atrophy treatments focus on slowing lesion progression, preserving remaining vision, and improving patients’ quality of life through targeted therapies and disease management strategies. In February 2023, Apellis Pharmaceuticals’ SYFOVRE™ (pegcetacoplan injection) was approved by the FDA as the first and only treatment for Geographic Atrophy. Clinical studies demonstrated that SYFOVRE significantly reduced lesion growth over 24 months with a well-established safety profile and flexible dosing every 25 to 60 days.
Epidemiological data indicate that geographic atrophy (GA) affects a significant population worldwide. According to Antoine Huang et al., 2025, the global prevalence of geographic atrophy is estimated at 0.44%, affecting approximately five million people worldwide. As per Vishal Saundankar et al., 2025, more than 1 million individuals in the United States are diagnosed with GA in at least one eye, accounting for 20% of legal blindness. According to Christiana Dinah et al., 2025, geographic atrophy represents around 26% of legal blindness in the United Kingdom. As per Chui Ming Gemmy Cheung et al., 2025, approximately 20% of patients in Japan present with the pachychoroid subphenotype. These data highlight the growing need for effective treatments and interventions for GA globally.
This section of the report covers the analysis of geographic atrophy drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The geographic atrophy pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II 57%, covers a major share of the total geographic atrophy clinical trials. It is followed by phase I 30%, and phase III 10%. This strong presence in early and mid-development phases highlights substantial research activity and innovation, which is expected to drive future treatment options, enhance patient outcomes, and positively impact the overall Geographic Atrophy market growth.
The drug molecule categories covered under the geographic atrophy pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The geographic atrophy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for geographic atrophy. Antibody fragment-based therapies are emerging as promising treatments for geographic atrophy. For instance, BI 771716, developed by Boehringer Ingelheim in collaboration with CDR-Life, is under investigation following positive Phase I results. This highly specific antibody fragment enables optimized retinal penetration to target GA pathology directly, potentially preserving vision and improving quality of life for patients living with this progressive form of age-related macular degeneration.
The EMR report for the geographic atrophy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed geographic atrophy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in geographic atrophy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for geographic atrophy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of geographic atrophy drug candidates.
BRX011, developed by BioJiva LLC, is an oral drug designed to slow the progression of geographic atrophy secondary to age-related macular degeneration. This Phase 1/2 study is examining the safety, tolerability, and efficacy of BRX011 when administered once daily to adults with this condition. BRX011 is an armored form of docosahexaenoic acid (DHA) that enhances visual acuity and adaptation to dim lighting by stabilizing rhodopsin in photoreceptor membranes. The study is actively monitoring participants over 96 weeks, assessing ocular health, adverse events, and the annual change in GA area, to determine the drug’s therapeutic potential.
JNJ-81201887 (AAVCAGsCD59) is an investigational gene therapy sponsored by Janssen Research & Development, LLC, currently being evaluated for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). This Phase 2b study is examining the change in GA lesion growth in eyes receiving JNJ-81201887 compared to a sham procedure, and the study is estimated to be completed by February, 2026. The drug is designed to increase expression of soluble CD59 (sCD59), protecting retinal cells and slowing disease progression. Patients are receiving intravitreal injections, and the trial is actively monitoring safety, efficacy, and optimal dosing outcomes.
ADX-038, developed by ADARx Pharmaceuticals, Inc., is an investigational siRNA therapy targeting complement factor B (CFB) to modulate the complement pathway. This Phase 2 study is assessing the efficacy of ADX-038 compared with placebo in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study is examining safety, pharmacokinetics, and pharmacodynamics while evaluating the drug’s potential to slow GA progression. The study is expected to be completed in December 2027, further establishing ADX-038’s potential in complement-mediated diseases.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Geographic Atrophy Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for geographic atrophy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into geographic atrophy collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share